[go: up one dir, main page]

MX2018006823A - Una composicion para mejorar la memoria, capacidad de aprendizaje y capacidad cognitiva. - Google Patents

Una composicion para mejorar la memoria, capacidad de aprendizaje y capacidad cognitiva.

Info

Publication number
MX2018006823A
MX2018006823A MX2018006823A MX2018006823A MX2018006823A MX 2018006823 A MX2018006823 A MX 2018006823A MX 2018006823 A MX2018006823 A MX 2018006823A MX 2018006823 A MX2018006823 A MX 2018006823A MX 2018006823 A MX2018006823 A MX 2018006823A
Authority
MX
Mexico
Prior art keywords
cognition
composition
improving memory
learning ability
peptide
Prior art date
Application number
MX2018006823A
Other languages
English (en)
Inventor
Kang Yongkoo
Original Assignee
Brainon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020150183011A external-priority patent/KR101706296B1/ko
Priority claimed from KR1020160026600A external-priority patent/KR101844481B1/ko
Application filed by Brainon Inc filed Critical Brainon Inc
Publication of MX2018006823A publication Critical patent/MX2018006823A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Psychology (AREA)

Abstract

Se proporciona una composición para mejorar la memoria, capacidad de aprendizaje y capacidad cognitiva. Se ha confirmado que un péptido que tiene una región C-terminal terminada a GAG tuvo un efecto para mejorar la memoria. Para que el péptido tenga el efecto, se ha confirmado que el péptido debería ser un péptido cuya longitud conste de al menos 4 aminoácidos. Además, se ha confirmado que un péptido cuya longitud del péptido que tiene la región C-terminal terminada en GAG consiste en 5 a 9 aminoácidos tiene el mismo efecto. Como resultado, el péptido de la presente invención puede usarse como la composición para mejorar la memoria, la capacidad de aprendizaje y la capacidad cognitiva.
MX2018006823A 2015-12-21 2016-05-03 Una composicion para mejorar la memoria, capacidad de aprendizaje y capacidad cognitiva. MX2018006823A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150183011A KR101706296B1 (ko) 2015-12-21 2015-12-21 기억력, 학습력, 인지력 향상용 조성물
KR1020160026600A KR101844481B1 (ko) 2016-03-04 2016-03-04 기억력 향상 효과를 가지는 펩타이드
PCT/KR2016/004650 WO2017111215A1 (ko) 2015-12-21 2016-05-03 기억력, 학습력, 인지력 향상용 조성물

Publications (1)

Publication Number Publication Date
MX2018006823A true MX2018006823A (es) 2018-11-29

Family

ID=59090692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006823A MX2018006823A (es) 2015-12-21 2016-05-03 Una composicion para mejorar la memoria, capacidad de aprendizaje y capacidad cognitiva.

Country Status (14)

Country Link
US (4) US20180201645A1 (es)
EP (1) EP3255055B1 (es)
JP (1) JP6463499B2 (es)
CN (2) CN107406482A (es)
AU (2) AU2016376059B2 (es)
CA (1) CA2965840C (es)
MX (1) MX2018006823A (es)
MY (1) MY197348A (es)
PH (1) PH12017550079A1 (es)
RU (1) RU2694064C1 (es)
SA (1) SA518391710B1 (es)
SG (1) SG11201804902UA (es)
TR (1) TR201807610T1 (es)
WO (1) WO2017111215A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743293C1 (ru) * 2020-07-06 2021-02-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Применение пептида Gly-His-Lys-Val-Glu-Pro для повышения обучаемости и улучшения памяти.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243038A (en) * 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
WO1988003533A1 (en) 1986-11-04 1988-05-19 Syntro Corporation Construction of synthetic dna and its use in large polypeptide synthesis
US5606019A (en) * 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
US6069129A (en) * 1998-03-13 2000-05-30 Mrs, Llc Elastin derived composition and method of using same
EP1104304A1 (en) * 1998-08-13 2001-06-06 G.D. Searle & Co. Multivalent avb3 and metastasis-associated receptor ligands
US6608242B1 (en) * 2000-05-25 2003-08-19 E. I. Du Pont De Nemours And Company Production of silk-like proteins in plants
AU2001282437A1 (en) * 2000-07-31 2002-02-13 Amidut Ltd. Detecting anti-viral drug candidates and resistance
DK1370276T3 (da) * 2001-02-22 2011-04-18 Zealand Pharma As Intracellulær kommunikations-lettende forbindelser og deres medicinske anvendelser
US7056889B2 (en) * 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
CN1532281A (zh) * 2003-03-21 2004-09-29 吉林大学第一医院 癌胚抗原基因片段的重组及基因疫苗
MXPA05012201A (es) * 2003-05-14 2006-02-10 Dow Corning Conjugados de agentes activos de polimero de proteina de secuencia de repeticion, metodos y usos.
US7148192B2 (en) 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
KR100494358B1 (ko) * 2004-07-30 2005-06-10 주식회사 바이오그랜드 두뇌 또는 인지 기능 증진용 조성물
KR20070000892A (ko) * 2005-06-28 2007-01-03 하성원 누에실크 피브로인의 재생방법
BRPI0614419A2 (pt) * 2005-08-16 2011-03-29 Copenhagen University peptìdeos derivados de gdnf
US8008259B2 (en) * 2005-11-07 2011-08-30 Copenhagen University, Techtrans Unit Neurotrophin-derived peptide sequences
EP1959968A2 (en) * 2005-12-06 2008-08-27 P2-Science APS Modulation of the p2y2 receptor pathway
WO2007124593A1 (en) * 2006-05-02 2007-11-08 Universite Laval Branched peptide amplification and uses thereof
KR100864380B1 (ko) * 2006-10-17 2008-10-21 주식회사 브레인가드 두뇌기능 향상과 뇌신경계 질환 예방 또는 치료용 펩타이드
US8247192B2 (en) * 2008-11-10 2012-08-21 Codexis, Inc. Penicillin-G acylases
CA2776295A1 (en) * 2009-09-02 2011-03-10 Kansas State University Research Foundation Mri and optical assays for proteases
US8916679B2 (en) * 2009-12-01 2014-12-23 Universita′ degli Studi di Modena e Reggio Emilia Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
CA2800744C (en) 2010-05-27 2018-09-04 Centocor Ortho Biotech Inc. Insulin-like growth factor 1 receptor binding peptides
JP2012017287A (ja) * 2010-07-07 2012-01-26 Iwate Univ 老齢性疾患治療薬
WO2012092718A1 (en) * 2011-01-07 2012-07-12 Nanjing University Photo-responsive supramolecular hydrogels
CN107782886A (zh) * 2011-04-21 2018-03-09 生物梅里埃公司 使用质谱检测至少一种头孢菌素抗性机制的方法
EP2970416B1 (en) * 2013-03-15 2023-11-22 Chugh, Sumant S. Methods for treatment of nephrotic syndrome and related conditions
KR20150114916A (ko) * 2014-04-02 2015-10-13 조아제약주식회사 기억력 증진 또는 집중력 향상 조성물
KR101430387B1 (ko) * 2014-04-08 2014-08-13 강용구 실크 피브로인 유래 펩타이드, 및 이를 포함하는 기억력, 학습력, 인지력의 향상 또는 치매의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
WO2017111215A1 (ko) 2017-06-29
RU2694064C1 (ru) 2019-07-09
US20220296673A1 (en) 2022-09-22
JP2018517394A (ja) 2018-07-05
CA2965840C (en) 2021-11-30
CN110279845B (zh) 2021-08-20
EP3255055C0 (en) 2024-06-05
PH12017550079A1 (en) 2018-02-12
EP3255055B1 (en) 2024-06-05
US10435436B2 (en) 2019-10-08
CA2965840A1 (en) 2017-06-29
CN107406482A (zh) 2017-11-28
BR112018012527A2 (pt) 2018-12-11
US20180327451A1 (en) 2018-11-15
TR201807610T1 (tr) 2018-06-21
EP3255055A4 (en) 2018-04-18
EP3255055A1 (en) 2017-12-13
SA518391710B1 (ar) 2022-11-09
CN110279845A (zh) 2019-09-27
SG11201804902UA (en) 2018-07-30
MY197348A (en) 2023-06-14
AU2016376059A1 (en) 2017-10-05
AU2016376059B2 (en) 2019-02-14
AU2019200449A1 (en) 2019-02-07
US20180327452A1 (en) 2018-11-15
JP6463499B2 (ja) 2019-02-06
US20180201645A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
PH12018501355A1 (en) Rsv f protein mutants
MX2021007020A (es) Dominios variables de inmunoglobulina mejorados.
MX389228B (es) Composiciones para tratar el cabello.
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
HK1252757A1 (zh) 用於降解错误折叠的蛋白质的组合物和方法
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
PH12018502714A1 (en) Nicotine particles and compositions
BR112016024494A8 (pt) análogo de peptídeo e seu uso
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2019014504A (es) Inmunoglobulinas de union a agrecano.
WO2015198240A3 (en) Compositions and methods for long acting proteins
PT3260437T (pt) Composição ácida à base de leonardita e aminoácidos
EP3360895A3 (en) Preparation comprising factor viii and von willebrand factor peptides
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
PH12017550079A1 (en) Composition for improving memory, learning ability and cognition
MX2015009867A (es) Mutantes del factor x.
NZ744289A (en) Composition containing amino acids
MX365952B (es) Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa.
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
NZ727444A (en) Prohemostatic proteins for the treatment of bleeding
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.
MX2020006670A (es) Composicion acuosa que comprende acido 2-(dimetil-1h-pirazol-1-il) succinico y amoniaco.
BR112018001207A2 (pt) novo peptídeo e uso do mesmo
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα